Figure 6
Effect of dinaciclib on in vivo tumor growth. (A) Dinaciclib in combination with gemcitabine significantly enhanced suppression of in vivo tumor growth than either of the treatments alone. (B) Western blot analysis of tumor samples from respective in vivo groups show reduction in expression of dinaciclib targets (CDK2/5/9) and anti-apoptotic proteins. Suppression in expression of these proteins was more pronounced in the combination treated group. Original uncropped western blot pictures are provided in supplemental material. (C) Representative immunofluorescence (IF) pictographs showing pHH3 positive stained cells (red) from vehicle and combination treated group. Bar graph showing average number of postitive pHH3 cells per mm2 of three samples each from vehicle and combination treated group. (D) Representaive immunohistochemistry (IHC) pictographs showing Ki-67 staining in vehicle and combination treated samples. Bar graph representing average number of Ki-67 positive cells of three samples each from vehicle and combination treated samples. Scale bar; IF = 20 µm and IHC = 100 µm. *p < 0.05.
